Vera Therapeutics (VERA) News Today $20.92 -0.23 (-1.09%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$20.98 +0.05 (+0.26%) As of 08:53 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VERA Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Vera Therapeutics, Inc. (NASDAQ:VERA) Given Consensus Recommendation of "Buy" by BrokeragesShares of Vera Therapeutics, Inc. (NASDAQ:VERA - Get Free Report) have been given an average recommendation of "Buy" by the ten ratings firms that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation, seven have assigned aJune 20 at 2:22 AM | marketbeat.comJ.P. Morgan Reaffirms Their Buy Rating on Vera Therapeutics (VERA)June 19 at 1:32 AM | theglobeandmail.comVera Therapeutics, Inc. (NASDAQ:VERA) Short Interest UpdateVera Therapeutics, Inc. (NASDAQ:VERA - Get Free Report) was the recipient of a large increase in short interest in the month of May. As of May 31st, there was short interest totalling 8,950,000 shares, an increase of 26.6% from the May 15th total of 7,070,000 shares. Based on an average daily volume of 1,580,000 shares, the days-to-cover ratio is currently 5.7 days. Approximately 18.6% of the company's shares are sold short.June 18 at 11:04 AM | marketbeat.comBrokers Offer Predictions for VERA FY2026 EarningsJune 13, 2025 | americanbankingnews.comWedbush Equities Analysts Raise Earnings Estimates for VERAJune 13, 2025 | americanbankingnews.comAnalysts Can't Get Enough of These Little-Known Biopharma Stocks (VERA)Three relatively unknown biopharma firms receive near-unanimous approval from analysts for their promising drug candidates in development.June 12, 2025 | marketbeat.comCantor Fitzgerald Comments on VERA FY2026 EarningsVera Therapeutics, Inc. (NASDAQ:VERA - Free Report) - Analysts at Cantor Fitzgerald issued their FY2026 earnings estimates for shares of Vera Therapeutics in a note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst P. Stavropoulos forecasts that the company will post earnings ofJune 11, 2025 | marketbeat.comQ2 EPS Estimates for Vera Therapeutics Increased by WedbushVera Therapeutics, Inc. (NASDAQ:VERA - Free Report) - Research analysts at Wedbush upped their Q2 2025 EPS estimates for Vera Therapeutics in a research report issued on Monday, June 9th. Wedbush analyst L. Chico now forecasts that the company will post earnings per share of ($0.70) for the quartJune 11, 2025 | marketbeat.comVera Therapeutics Inc.June 10, 2025 | barrons.comVera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 9, 2025 | globenewswire.comVera Therapeutics (NASDAQ:VERA) Stock Price Down 5.2% - Here's What HappenedVera Therapeutics (NASDAQ:VERA) Trading Down 5.2% - Here's What HappenedJune 9, 2025 | marketbeat.comOtsuka's kidney disease therapy trial results heat up battle with rival VeraJune 6, 2025 | msn.comVera Therapeutics (NASDAQ:VERA) Shares Gap Down - Should You Sell?Vera Therapeutics (NASDAQ:VERA) Shares Gap Down - Here's WhyJune 6, 2025 | marketbeat.comBank of America Corp DE Sells 106,673 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA)Bank of America Corp DE reduced its position in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 77.9% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 30,244 shares of the company's stock after selling 106,673 shares dJune 6, 2025 | marketbeat.comWedbush Increases Earnings Estimates for Vera TherapeuticsVera Therapeutics, Inc. (NASDAQ:VERA - Free Report) - Equities research analysts at Wedbush raised their FY2027 earnings per share (EPS) estimates for Vera Therapeutics in a research note issued to investors on Monday, June 2nd. Wedbush analyst L. Chico now expects that the company will post earnJune 5, 2025 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Increases Position in Vera Therapeutics, Inc. (NASDAQ:VERA)UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 30.1% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 80,106 shares of the comJune 5, 2025 | marketbeat.comScotiabank Increases the Price Target for Vera Therapeutics by $10June 4, 2025 | msn.comVera Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare ConferenceJune 4, 2025 | globenewswire.comVera Therapeutics Atacicept: Promising Step In IgAN, But Crowded Road Ahead (Rating Downgrade)June 4, 2025 | seekingalpha.comFY2025 EPS Estimate for Vera Therapeutics Lowered by AnalystVera Therapeutics, Inc. (NASDAQ:VERA - Free Report) - Equities researchers at HC Wainwright reduced their FY2025 earnings per share (EPS) estimates for Vera Therapeutics in a note issued to investors on Monday, June 2nd. HC Wainwright analyst A. He now anticipates that the company will earn ($3.4June 4, 2025 | marketbeat.comVera Therapeutics (NASDAQ:VERA) Price Target Raised to $65.00 at ScotiabankScotiabank upped their price objective on Vera Therapeutics from $55.00 to $65.00 and gave the stock a "sector outperform" rating in a research note on Monday.June 3, 2025 | marketbeat.comVera Therapeutics Enters $500M Credit Facility As It Nears FDA Filing For Kidney Disease Drug: Retail Sees Stock Touching $40June 3, 2025 | msn.comVera Therapeutics (NASDAQ:VERA) Sees Unusually-High Trading Volume on Analyst UpgradeVera Therapeutics (NASDAQ:VERA) Sees Large Volume Increase on Analyst UpgradeJune 3, 2025 | marketbeat.comVera Therapeutics announces refinancing of Oxford debt facility with access to up to $500M in term loansJune 3, 2025 | msn.comVera Therapeutics Announces Refinancing of Existing Oxford Debt Facility, Providing up to $500 Million of Term LoansJune 3, 2025 | finance.yahoo.comVera Therapeutics Announces Refinancing of Existing Oxford Debt Facility, Providing up to $500 Million of Term LoansJune 3, 2025 | globenewswire.comQ2 Earnings Forecast for VERA Issued By Lifesci CapitalVera Therapeutics, Inc. (NASDAQ:VERA - Free Report) - Research analysts at Lifesci Capital issued their Q2 2025 EPS estimates for shares of Vera Therapeutics in a report issued on Monday, June 2nd. Lifesci Capital analyst R. Katkhuda forecasts that the company will post earnings of ($0.82) per shJune 3, 2025 | marketbeat.comWhy Vera Therapeutics, Inc. (VERA) Skyrocketed On MondayJune 3, 2025 | msn.comVera Therapeutics Shares Climb on Positive Trial Results for Kidney Disease DrugJune 2, 2025 | marketwatch.comVera Therapeutics Shares Jump 80% on Strong Phase 3 Trial Results for AtaciceptJune 2, 2025 | msn.comVera rises after success in late-stage trial for IgA nephropathy treatmentJune 2, 2025 | msn.comVera Therapeutics (NASDAQ:VERA) Shares Gap Up After Analyst UpgradeVera Therapeutics (NASDAQ:VERA) Shares Gap Up Following Analyst UpgradeJune 2, 2025 | marketbeat.comVera shares skyrocket as kidney disease drug succeeds in late-stage trialJune 2, 2025 | reuters.comKidney Health-Focused Vera Therapeutics Stock Price Spikes On Heels Of Successful Trial DataJune 2, 2025 | benzinga.comVera Therapeutics (NASDAQ:VERA) Price Target Raised to $85.00 at HC WainwrightHC Wainwright increased their price objective on Vera Therapeutics from $75.00 to $85.00 and gave the company a "buy" rating in a report on Monday.June 2, 2025 | marketbeat.comVera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA NephropathyJune 2, 2025 | globenewswire.comMillennium Management LLC Trims Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA)Millennium Management LLC decreased its holdings in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 73.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 77,648 shares of the company's stock after seJune 1, 2025 | marketbeat.comVera Therapeutics (NASDAQ:VERA) Stock Price Up 5.7% - Time to Buy?Vera Therapeutics (NASDAQ:VERA) Trading Up 5.7% - Here's WhyMay 30, 2025 | marketbeat.comVera Therapeutics, Inc. (NASDAQ:VERA) Given Average Rating of "Buy" by AnalystsVera Therapeutics, Inc. (NASDAQ:VERA - Get Free Report) has received a consensus rating of "Buy" from the ten analysts that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation, seven have assigned a buy recommendation anMay 27, 2025 | marketbeat.comCantor Fitzgerald maintains Vera Therapeutics at OverweightMay 26, 2025 | uk.investing.comBNP Paribas Financial Markets Purchases Shares of 24,374 Vera Therapeutics, Inc. (NASDAQ:VERA)BNP Paribas Financial Markets purchased a new stake in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 24,374 shares of the company's stock, valued at approximately $1,031,00May 23, 2025 | marketbeat.comWoodline Partners LP Acquires 201,573 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA)Woodline Partners LP raised its holdings in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 20.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,202,466 shares of the company's stock after acquiring an additional 201,573May 22, 2025 | marketbeat.comMarker Therapeutics CEO Dr. Juan Vera to Join Expert Panel Discussing CD19 CAR-T Therapy at Upcoming WebcastMay 21, 2025 | nasdaq.comVestal Point Capital LP Acquires Shares of 1,075,000 Vera Therapeutics, Inc. (NASDAQ:VERA)Vestal Point Capital LP bought a new stake in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 1,075,000 shares of the company's stock, valued at approximately $45May 21, 2025 | marketbeat.comThornburg Investment Management Inc. Acquires 28,124 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA)Thornburg Investment Management Inc. raised its stake in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 91.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 59May 21, 2025 | marketbeat.comVera Therapeutics, Inc. (NASDAQ:VERA) Shares Acquired by Point72 Asset Management L.P.Point72 Asset Management L.P. lifted its position in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 13.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 194,027 shares of the company's stock afMay 21, 2025 | marketbeat.comD. E. Shaw & Co. Inc. Decreases Stock Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA)D. E. Shaw & Co. Inc. trimmed its holdings in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 42.9% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 74,476 shares of the company's stock after selling 55,990 sMay 21, 2025 | marketbeat.comMPM Bioimpact LLC Acquires New Position in Vera Therapeutics, Inc. (NASDAQ:VERA)MPM Bioimpact LLC bought a new position in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 257,788 shares of the company's stock, valued at approximately $10,902,00May 16, 2025 | marketbeat.comVera Therapeutics, Inc. (NASDAQ:VERA) Shares Acquired by Paradigm Biocapital Advisors LPParadigm Biocapital Advisors LP boosted its stake in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 31.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,437,339 shares of the compaMay 16, 2025 | marketbeat.comVera Therapeutics, Inc. (NASDAQ:VERA) Shares Purchased by Nicholas Investment Partners LPNicholas Investment Partners LP lifted its holdings in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 49.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 106,805 shares of the company's stock aMay 16, 2025 | marketbeat.com Get Vera Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VERA and its competitors with MarketBeat's FREE daily newsletter. Email Address VERA Media Mentions By Week VERA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VERA News Sentiment▼0.550.69▲Average Medical News Sentiment VERA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VERA Articles This Week▼56▲VERA Articles Average Week Get Vera Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VERA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Nuvalent News Today Lantheus News Today Axsome Therapeutics News Today ADMA Biologics News Today Zai Lab News Today Akero Therapeutics News Today Vaxcyte News Today PTC Therapeutics News Today Cytokinetics News Today Rhythm Pharmaceuticals News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VERA) was last updated on 6/20/2025 by MarketBeat.com Staff From Our PartnersPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredWhy Is President Trump Fast-Tracking These Companies?Forget about AI… There's a hot new trend on Wall Street… and it's all thanks to President Trump. His administr...InvestorPlace | SponsoredMost Bitcoin holders have no idea this existsHere’s what 99% of Bitcoin holders don’t know: There’s a way to amplify your Bitcoin gains without buying m...Brownstone Research | SponsoredWar-Proof Power Why This "Weird" Government Land Auction Was No Ordinary Sale When 218,000 acres of land... smack in the m...Stansberry Research | Sponsored50-year legend: Here’s exact day stocks will crashGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vera Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy VERA Stock Free VERA Stock Alerts